Previous Close | 13.18 |
Open | 13.15 |
Bid | 0.00 x 900 |
Ask | 0.00 x 900 |
Day's Range | 12.72 - 13.75 |
52 Week Range | 3.84 - 13.79 |
Volume | |
Avg. Volume | 524,379 |
Market Cap | 757.097M |
Beta (5Y Monthly) | 0.68 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.88 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for TCDA
SOUTH SAN FRANCISCO, Calif., August 08, 2022--Tricida Announces Second Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022. Tricida will host a webcast and conference call at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows: Tricida Second Quarter Financial Results Conference CallMonday, August 8, 20224:30 pm
Tricida Inc (NASDAQ: TCDA) said that, as anticipated, it is stopping its VALOR-CKD renal outcomes trial early for administrative reasons under the existing study protocol to allow for six months of financial runway following topline results, currently anticipated in early Q4 2022. VALOR-CKD trial, initiated in 2018, was designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and CKD. As of May 18, the average treatment duration of the 1480 subjects wa